Cargando…

Reply: Did animal offer relevant model for bevacizumab testing?

Detalles Bibliográficos
Autores principales:	Bozec, A, Sudaka, A, Fischel, J L, Brunstein, M C, Grimaldi, M C, Milano, G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579689/ http://dx.doi.org/10.1038/sj.bjc.6604694

Ejemplares similares

Did animal offer relevant model for Bevacizumab testing?
por: Eveno, C, et al.
Publicado: (2008)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

The Author's Reply to “Did This Cryptococcosis Patient Have HIV Coinfection?”
por: Sato, Shuku
Publicado: (2019)

EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment
por: Guérin, Olivier, et al.
Publicado: (2010)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Did food allergy develop in the process of animal evolution?
por: Nabavizadeh, Seyed Hesamedin, et al.
Publicado: (2016)

Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'
por: Schirripa, M, et al.
Publicado: (2013)

Reply: On the clinical relevance of circulating endothelial cells and platelets in prostate cancer
por: Wong, C K E, et al.
Publicado: (2013)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Reply to: When did mammoths go extinct?
por: Wang, Yucheng, et al.
Publicado: (2022)

Author's Reply: Why Did the Patient Not Show Any Neurological Symptoms on the Day of the Higher Serum Concentration of Ceftriaxone?
por: Suzuki, Soichiro, et al.
Publicado: (2019)

In Reply: Trough Melatonin Levels Have No Physiological or Clinical Relevance
por: Lin, Chieh-Hsin, et al.
Publicado: (2021)

Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas
por: Veracini, Laurence, et al.
Publicado: (2014)

Intravitreal bevacizumab
por: Khamar, Bakulesh M
Publicado: (2018)

Schematherapy in DID: treatment length and related studies on dissociative amnesia
por: Huntjens, R. J. C., et al.
Publicado: (2020)

Author’s Reply
por: Najar, M. S., et al.
Publicado: (2010)

Reply
por: Villaverde, Serena, et al.
Publicado: (2021)

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Novello, S, et al.
Publicado: (2010)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease: Author's Reply
por: Hong, Su Jin
Publicado: (2013)

Liver function test abnormalities and their clinical relevance in primary myelofibrosis
por: Barraco, D, et al.
Publicado: (2017)

Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
por: Schechet, Sidney A., et al.
Publicado: (2019)

Reply
por: Harahsheh, Ashraf S., et al.
Publicado: (2020)

Reply
por: Satija, D.C.
Publicado: (1990)

Author's Reply
por: Bhalla, Ashu S, et al.
Publicado: (2018)

Authors’ reply
por: Bharathi, M Jayahar, et al.
Publicado: (2012)

In Reply—Repeated Testing in SARS-CoV-2 Infection
por: Shah, Aditya, et al.
Publicado: (2020)

Authors' reply
por: Malik, Arshad M, et al.
Publicado: (2007)

In Reply
por: de Velasco, Guillermo, et al.
Publicado: (2017)

Reply: antioxidant trials—the need to test for stress
por: Kamath, Mohan S, et al.
Publicado: (2021)

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis
por: Marchetti, S, et al.
Publicado: (2001)

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

Authors’ reply
por: Gupta, Bharti, et al.
Publicado: (2011)

Reply
por: Goldman, Ran D., et al.
Publicado: (2021)

Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.
por: Bernard, S., et al.
Publicado: (1991)

Author's reply
por: Srivastava, A., et al.
Publicado: (2007)

Severe epistaxis related to intravitreal bevacizumab
por: Otten, Leila S., et al.
Publicado: (2019)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

Reply
por: Krüger, Martin, et al.
Publicado: (2021)

Authors' reply
por: Jasuja, S., et al.
Publicado: (2009)

Chest wall injury centers—how we did it
por: Forrester, Joseph D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6eiqheoarlvh9t6ta6naijt6uc